AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1683094 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptics alone (control group)
Number of subjects: 0
Study 6803871 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (480 mg daily)
Number of subjects: 0
Study 6803871 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (60 mg daily)
Number of subjects: 0
Study 6803871 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (480 mg daily) during cold pressor test
Number of subjects: 0
Study 6803871 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (60 mg daily) during cold pressor test
Number of subjects: 0
Study 6803871 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (480 mg daily) during mental arithmetic test
Number of subjects: 0
Study 6803871 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (60 mg daily) during mental arithmetic test
Number of subjects: 0
Study 6803871 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine and Propranolol together
Number of subjects: 0
Study 30894063 — intervention group
Group type: EXPERIMENTAL
Intervention: Rumination
Number of subjects: 0
Study 30894063 — intervention group
Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 0
Study 30894063 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (Rumination and Distraction)
Number of subjects: 0
Study 30063804 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose MSCs (ASCs) at 4 × 106 cells/kg
Number of subjects: 32
Study 30063804 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose MSCs (ASCs) at 1 × 106 cells/kg
Number of subjects: 32
Study 30063804 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic adipose MSCs (ASCs) at 0.25 × 106 cells/kg
Number of subjects: 32
Study 30063804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 27440681 — intervention group
Group type: COMPARATOR
Intervention: C80
Number of subjects: 40
Study 27440681 — intervention group
Group type: EXPERIMENTAL
Intervention: HF meals
Number of subjects: 40
Study 27440681 — intervention group
Group type: EXPERIMENTAL
Intervention: HF200
Number of subjects: 40
Study 27440681 — intervention group
Group type: COMPARATOR
Intervention: C200 and C280
Number of subjects: 40
Study 24535626 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU every 4 weeks)
Number of subjects: 203
Study 24535626 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 203
Study 22728943 — intervention group
Group type: EXPERIMENTAL
Intervention: Echinacea (ECH)
Number of subjects: 24
Study 19143915 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible-dose sildenafil (50 or 100 mg)
Number of subjects: 209
Study 17567823 — intervention group
Group type: EXPERIMENTAL
Intervention: ALERT Plus program (basic curriculum extended to ninth grade with five booster lessons)
Number of subjects: 0
Study 17567823 — intervention group
Group type: COMPARATOR
Intervention: Control schools (basic ALERT curriculum covering seventh and eighth grades only)
Number of subjects: 0
Study 16146457 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG patients
Number of subjects: 393
Study 16146457 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 393
Study 12187064 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential methotrexate and 5-fluorouracil scheduling, epirubicin and cisplatin (MFAP regimen)
Number of subjects: 37
Study 12187064 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder preservation
Number of subjects: 37
Study 12187064 — intervention group
Group type: COMPARATOR
Intervention: Cystectomy group
Number of subjects: 37
Study 10442596 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary caloric intake (88.1 ± 5.0 kcal/kg/d; range, 60 to 113 kcal/kg/d)
Number of subjects: 12
Study 10442596 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary caloric intake
Number of subjects: 12
Study 8702200 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic surgery (VATS)
Number of subjects: 24
Study 8702200 — intervention group
Group type: COMPARATOR
Intervention: Thoracotomy (T-group)
Number of subjects: 24
Study 2327561 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitization with extract from the house dust mite Dermatophagoides pteronyssinus (Dp) for 2 years
Number of subjects: 31
Study 2327561 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyposensitization with extract from the house dust mite Dermatophagoides pteronyssinus (Dp)
Number of subjects: 31
Study 2327561 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 comparable patients)
Number of subjects: 31
Study 343250 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride (up to 10 mg)
Number of subjects: 30
Study 343250 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 30
Study 30830540 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant dendritic cell therapy
Number of subjects: 120
Study 30830540 — intervention group
Group type: EXPERIMENTAL
Intervention: Local treatment with curative intent
Number of subjects: 120
Study 30830540 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic treatment
Number of subjects: 120
Study 29793126 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT)
Number of subjects: 42
Study 29793126 — intervention group
Group type: COMPARATOR
Intervention: Proprioceptive Neuromuscular Facilitation (PNF)
Number of subjects: 42
Study 27399503 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS) with Apollo device
Number of subjects: 222
Study 27399503 — intervention group
Group type: COMPARATOR
Intervention: Best medical management (MM)
Number of subjects: 222
Study 24670148 — intervention group
Group type: EXPERIMENTAL
Intervention: Paromomycin-miltefosine combination therapy
Number of subjects: 0
Study 22987089 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine supplementation (2 g/d)
Number of subjects: 376
Study 22987089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study 18755818 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 10 mg
Number of subjects: 30
Study 18755818 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibutramine 15 mg
Number of subjects: 30
Study 18755818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18001445 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin discontinued at the beginning of the active phase of labor
Number of subjects: 342
Study 18001445 — intervention group
Group type: COMPARATOR
Intervention: Oxytocin continued until delivery
Number of subjects: 342
Study 15958169 — intervention group
Group type: EXPERIMENTAL
Intervention: Total plaque volume measurement in subjects with diabetes/impaired glucose tolerance
Number of subjects: 98
Study 15958169 — intervention group
Group type: EXPERIMENTAL
Intervention: Intima-media thickness measurement in subjects with diabetes/impaired glucose tolerance
Number of subjects: 98
Study 15958169 — intervention group
Group type: COMPARATOR
Intervention: Total plaque volume measurement in normoglycemic controls
Number of subjects: 98
Study 15958169 — intervention group
Group type: COMPARATOR
Intervention: Intima-media thickness measurement in normoglycemic controls
Number of subjects: 98
Study 12131259 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation (20 g.d‐1 Cr + 180 g.d‐1 dextrose)
Number of subjects: 32
Study 12131259 — intervention group
Group type: COMPARATOR
Intervention: Placebo (200 g.d‐1 dextrose)
Number of subjects: 32
Study 12131259 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation
Number of subjects: 32
Study 10765887 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects with 25 or more teeth (dentate)
Number of subjects: 225
Study 10765887 — intervention group
Group type: COMPARATOR
Intervention: Edentulous subjects
Number of subjects: 225
Study 7588171 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100-300 mg (mean daily dose 204 mg)
Number of subjects: 40
Study 7588171 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine 50-150 mg (mean daily dose 106 mg)
Number of subjects: 40
Study 7588171 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 40
Study 2254102 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy (IHF) - 23 Gy in 4 fractions over 17 days
Number of subjects: 230
Study 2254102 — intervention group
Group type: COMPARATOR
Intervention: Classical radiation therapy (IC) - 45 Gy in 25 fractions over 33 days
Number of subjects: 230
Study 2254102 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiation therapy (IHF)
Number of subjects: 230
Study 2254102 — intervention group
Group type: COMPARATOR
Intervention: Classical radiation therapy (IC)
Number of subjects: 230
Study 6782869 — intervention group
Group type: EXPERIMENTAL
Intervention: Travasol 8.5%
Number of subjects: 36
Study 6782869 — intervention group
Group type: COMPARATOR
Intervention: FreAmine II 8.5%
Number of subjects: 36
Study 29630433 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy with concurrent systemic therapy
Number of subjects: 20
Study 27215779 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (20 mg/kg loading dose within 24 hours of birth, followed by 7.5 mg/kg every 6 hours for 4 days)
Number of subjects: 48
Study 27215779 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.45% NaCl)
Number of subjects: 48
Study 24534379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 612
Study 22574568 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcing manipulation of acupuncture
Number of subjects: 60
Study 22574568 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing manipulation of acupuncture
Number of subjects: 60
Study 22574568 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-retaining group
Number of subjects: 60
Study 22574568 — intervention group
Group type: COMPARATOR
Intervention: Model group
Number of subjects: 60
Study 20697273 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ocular surface medium (TOSM)
Number of subjects: 46
Study 18424191 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (75 mg once daily for 2 weeks, 150 mg once daily for 4 weeks, and 75 mg once daily for 2 weeks)
Number of subjects: 160
Study 18424191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 15860246 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/day glipizide GITS
Number of subjects: 122
Study 15860246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 12933400 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemisync sounds
Number of subjects: 60
Study 12933400 — intervention group
Group type: COMPARATOR
Intervention: Control group (blank cassette tape)
Number of subjects: 60
Study 11732515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg rectally with i.v. placebo
Number of subjects: 123
Study 11732515 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 25 mg i.v. with rectal placebo
Number of subjects: 123
Study 11732515 — intervention group
Group type: COMPARATOR
Intervention: Placebo both i.v. and rectally
Number of subjects: 123
Study 8868334 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-hemispheric P50m response (141.5 +/- 16.3 fT)
Number of subjects: 37
Study 8868334 — intervention group
Group type: COMPARATOR
Intervention: Right-hemispheric P50m response (135.1 +/- 11.0 fT)
Number of subjects: 37
Study 8868334 — intervention group
Group type: EXPERIMENTAL
Intervention: Right-hemispheric N100m response (484.4 +/- 28.4 fT)
Number of subjects: 37
Study 8868334 — intervention group
Group type: COMPARATOR
Intervention: Right-hemispheric N100m response (405.8 +/- 27.9 fT)
Number of subjects: 37
Study 1320919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous granisetron 40 micrograms/kg
Number of subjects: 996
Study 1320919 — intervention group
Group type: COMPARATOR
Intervention: Intravenous granisetron 10 micrograms/kg
Number of subjects: 996
Study 1320919 — intervention group
Group type: COMPARATOR
Intervention: Intravenous granisetron 2 micrograms/kg
Number of subjects: 996
Study 1320919 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous granisetron 3 mg single-dose regimen (equivalent to 40 micrograms/kg in a 75 kg person)
Number of subjects: 996
Study 6468816 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenon (900 mg/day)
Number of subjects: 12
Study 6468816 — intervention group
Group type: COMPARATOR
Intervention: Mexiletine (600 mg/day)
Number of subjects: 12
Study 30895903 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical cerclage
Number of subjects: 25
Study 30895903 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal pessary
Number of subjects: 25
Study 30895903 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone 200 mg nocte
Number of subjects: 25
Study 30895903 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 25
Study 30352748 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000 IU/day)
Number of subjects: 127
Study 30352748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 30191830 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated intervention (systems navigation, psychosocial counselling, ART at any CD4 count)
Number of subjects: 1308
Study 30191830 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1308
Study 27130691 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 200 mg every 2 weeks
Number of subjects: 769
Study 27130691 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks
Number of subjects: 769
Study 27130691 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (both doses)
Number of subjects: 769
Study 27130691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 769
Study 25042759 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Recovery Group (WRG), n=52
Number of subjects: 158
Study 25042759 — intervention group
Group type: COMPARATOR
Intervention: Group Drug Counseling (GDC), n=48
Number of subjects: 158
Study 22713087 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium phosphate (NaP) tablets
Number of subjects: 92
Study 22713087 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol (PEG) solution
Number of subjects: 92
Study 21162959 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch 130/0.4 (HES 130/0.4)
Number of subjects: 80
Study 21162959 — intervention group
Group type: COMPARATOR
Intervention: 4% succinylated gelatine
Number of subjects: 80
Study 21162959 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (H and G)
Number of subjects: 80
Study 17670801 — intervention group
Group type: EXPERIMENTAL
Intervention: Red wine (150 ml, 15 g alcohol) daily for 3 weeks
Number of subjects: 87
Study 15572657 — intervention group
Group type: EXPERIMENTAL
Intervention: CAA supplements (15 g of essential amino acids and 30 g of carbohydrate)
Number of subjects: 13
Study 15572657 — intervention group
Group type: EXPERIMENTAL
Intervention: CAA ingestion
Number of subjects: 13
Study 15572657 — intervention group
Group type: COMPARATOR
Intervention: Liquid mixed meal (CON)
Number of subjects: 13
Study 11874393 — intervention group
Group type: COMPARATOR
Intervention: (+)-chlorpheniramine 2 mg
Number of subjects: 12
Study 11874393 — intervention group
Group type: COMPARATOR
Intervention: (+)-chlorpheniramine 6 mg
Number of subjects: 12
Study 11874393 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11874393 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebastine 10 mg
Number of subjects: 12
Study 9664997 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral
Number of subjects: 30
Study 9664997 — intervention group
Group type: COMPARATOR
Intervention: Sandimmune
Number of subjects: 30
Study 7540512 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemodilution (haematocrit = 28%-32%)
Number of subjects: 32
Study 7540512 — intervention group
Group type: COMPARATOR
Intervention: Nonhaemodiluted group
Number of subjects: 32
Study 2142968 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate and ethinylestradiol (2 mg cyproterone acetate + 0.035 mg ethinyl‐estradiol days 1‐21, +10 mg cyproterone acetate days 1‐15) (n = 15)
Number of subjects: 28
Study 2142968 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone (0.25‐0.5 mg daily at 10 pm) (n = 13)
Number of subjects: 28
Study 769201 — intervention group
Group type: EXPERIMENTAL
Intervention: Sengstaken‐Blakemore tube
Number of subjects: 28
Study 769201 — intervention group
Group type: COMPARATOR
Intervention: Linton‐Nachlas tube
Number of subjects: 28
Study 31222832 — intervention group
Group type: COMPARATOR
Intervention: Standard Monitoring (SM)
Number of subjects: 150
Study 31222832 — intervention group
Group type: EXPERIMENTAL
Intervention: Capnography (CA)
Number of subjects: 150
Study 30676139 — intervention group
Group type: EXPERIMENTAL
Intervention: HYPER (FiO2: 0.36)
Number of subjects: 15
Study 30676139 — intervention group
Group type: EXPERIMENTAL
Intervention: NORM‐DEC (FiO2: 0.36)
Number of subjects: 15
Study 30676139 — intervention group
Group type: EXPERIMENTAL
Intervention: NORM‐INFORM (FiO2: 0.21)
Number of subjects: 15
Study 30676139 — intervention group
Group type: COMPARATOR
Intervention: NORM (FiO2: 0.21)
Number of subjects: 15
Study 29216945 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass (CPB)
Number of subjects: 40
Study 29216945 — intervention group
Group type: COMPARATOR
Intervention: Control group (off‐pump ligation of ductus arteriosus)
Number of subjects: 40
Study 25609246 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 25609246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganitumab 12 mg/kg
Number of subjects: 800
Study 25609246 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganitumab 20 mg/kg
Number of subjects: 800
Study 23710586 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation (CRT) with cisplatin 40 mg/m² weekly × 5
Number of subjects: 305
Study 23710586 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 305
Study 16818817 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 1000
Study 16818817 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 1000
Study 16818817 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy
Number of subjects: 1000
Study 16818817 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy in NYHA class II
Number of subjects: 1000
Study 16818817 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy in NYHA class III
Number of subjects: 1000
Study 10760105 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional parameters (dietary protein intake, energy intake, serum albumin, transferrin, percentage body fat, skinfold thickness, urine creatinine excretion)
Number of subjects: 1785
Study 10760105 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein and energy intakes
Number of subjects: 1785
Study 10760105 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthropometric and biochemical nutritional parameters
Number of subjects: 1785
Study 8614710 — intervention group
Group type: EXPERIMENTAL
Intervention: Single lumen catheters
Number of subjects: 188
Study 8614710 — intervention group
Group type: COMPARATOR
Intervention: Double lumen catheters
Number of subjects: 188
Study 1569387 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleate-diet (12.0% energy from linoleic acid)
Number of subjects: 56
Study 1569387 — intervention group
Group type: EXPERIMENTAL
Intervention: Stearate-diet (11.8% energy from stearic acid)
Number of subjects: 56
Study 1569387 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-diet (7.7% energy from trans fatty acids)
Number of subjects: 56
Study 3912623 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 40 mg daily for 2 years
Number of subjects: 826
Study 3912623 — intervention group
Group type: COMPARATOR
Intervention: No endocrine treatment
Number of subjects: 826
Study 30634393 — intervention group
Group type: EXPERIMENTAL
Intervention: lactofermented Annurca apple puree (lfAAP)
Number of subjects: 90
Study 30634393 — intervention group
Group type: COMPARATOR
Intervention: unfermented apple puree (AAP)
Number of subjects: 90
Study 30634393 — intervention group
Group type: COMPARATOR
Intervention: probiotic alone (LAB)
Number of subjects: 90
Study 27890473 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who ate alone for one session in the absence of social influence
Number of subjects: 0
Study 27890473 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who ate alone for two or three prior sessions
Number of subjects: 0
Study 27890473 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who ate alone for three sessions prior to exposure to high eating norm
Number of subjects: 0
Study 27890473 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who ate alone following a session with norm-setting remote confederates
Number of subjects: 0
Study 27890473 — intervention group
Group type: EXPERIMENTAL
Intervention: Low eating norm
Number of subjects: 0
Study 27890473 — intervention group
Group type: EXPERIMENTAL
Intervention: High eating norm
Number of subjects: 0
Study 25119511 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg IBUNa (Advil Film Coated Tablets)
Number of subjects: 316
Study 25119511 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg IBUAdv (standard ibuprofen)
Number of subjects: 316
Study 25119511 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg IBUMot (standard ibuprofen)
Number of subjects: 316
Study 25119511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316
Study 23670357 — intervention group
Group type: EXPERIMENTAL
Intervention: No-load condition (body weight)
Number of subjects: 13
Study 23670357 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical jumps with stretch-shortening cycle (SSC)
Number of subjects: 13
Study 21307868 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan
Number of subjects: 31
Study 21307868 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 31
Study 18555744 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich fish oil (6 g/day)
Number of subjects: 25